Блог Стаса: Drug Safety and Availability FDA Drug Safety Communication: Safety review of post-market reports of serious bleeding events with the anticoagulant Pradaxa (dabigatran etexilate mesylate)

четверг, 12 января 2012 г.

Drug Safety and Availability FDA Drug Safety Communication: Safety review of post-market reports of serious bleeding events with the anticoagulant Pradaxa (dabigatran etexilate mesylate)

Drug Safety and Availability FDA Drug Safety Communication: Safety review of post-market reports of serious bleeding events with the anticoagulant Pradaxa (dabigatran etexilate mesylate)

Комментариев нет:

Отправить комментарий

Подписаться на: Комментарии к сообщению (Atom)